• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Astrocytoma - Pipeline Review, H2 2012 Product Image

Astrocytoma - Pipeline Review, H2 2012

  • ID: 2233592
  • August 2012
  • 216 pages
  • Global Markets Direct

Astrocytoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Astrocytoma - Pipeline Review, H2 2012', provides an overview of the Astrocytoma therapeutic pipeline. This report provides information on the therapeutic development for Astrocytoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Astrocytoma. 'Astrocytoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Astrocytoma.
- A review of the Astrocytoma products under development by companies and universities/research institutes based on information derived from company READ MORE >

2
List of Tables 8
List of Figures 11
Introduction 12
REPORT COVERAGE 12
Astrocytoma Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Astrocytoma 14
Astrocytoma Therapeutics under Development by Companies 16
Astrocytoma Therapeutics under Investigation by Universities/Institutes 23
Late Stage Products 31
Comparative Analysis 31
Mid Clinical Stage Products 32
Comparative Analysis 32
Early Clinical Stage Products 33
Comparative Analysis 33
Discovery and Pre-Clinical Stage Products 34
Comparative Analysis 34
Astrocytoma Therapeutics – Products under Development by Companies 35
Astrocytoma Therapeutics – Products under Investigation by Universities/Institutes 42
Companies Involved in Astrocytoma Therapeutics Development 58
F. Hoffmann-La Roche Ltd. 58
Amgen Inc. 59
Sanofi-Aventis 60
AstraZeneca PLC 61
Eli Lilly and Company 62
Genentech, Inc. 63
MedImmune LLC 64
Merck & Co., Inc. 65
Lentigen Corporation 66
Sangamo BioSciences, Inc. 67
Plexxikon Inc. 68
Celltrion, Inc. 69
Ark Therapeutics Group plc 70
Novartis AG 71
Actelion Ltd 72
Eisai Co., Ltd. 73
Nippon Shinyaku Co., Ltd. 74
Pfizer Inc. 75
Cell Therapeutics, Inc. 76
Exelixis, Inc. 77
Aduro BioTech 78
Merck KGaA 79
Novartis Pharmaceuticals Corporation 80
Celldex Therapeutics, Inc. 81
ImmunoCellular Therapeutics, Ltd. 82
Lixte Biotechnology Holdings, Inc. 83
Northwest Biotherapeutics, Inc. 84
Cleveland BioLabs, Inc. 85
Oncothyreon Inc 86
Peregrine Pharmaceuticals, Inc. 87
Pharmacyclics, Inc. 88
PhytoMedical Technologies, Inc. 89
Transgene SA 90
Prana Biotechnology Limited 91
Threshold Pharmaceuticals, Inc. 92
Proximagen Neuroscience plc. 93
Rexahn Pharmaceuticals, Inc. 94
Spectrum Pharmaceuticals, Inc. 95
INSYS Therapeutics, Inc. 96
Ambit Biosciences Corporation 97
Immupharma Plc 98
Adnexus Therapeutics, Inc. 99
immatics biotechnologies GmbH 100
Apogenix GmbH 101
Diffusion Pharmaceuticals LLC 102
MacroGenics, Inc. 103
Fina Biotech 104
Nobelpharma Co., Ltd. 105
Deciphera Pharmaceuticals, LLC 106
Vascular Biogenics Ltd. 107
Stemline Therapeutics, Inc. 108
BioCancell Therapeutics, Inc. 109
Axelar AB 110
Advenchen Laboratories, LLC 111
Viral Genetics, Inc. 112
Myriad Pharmaceuticals, Inc. 113
NOXXON Pharma AG 114
ChemoCentryx, Inc. 115
TVAX Biomedical, LLC 116
Sirnaomics, Inc. 117
ZGene A/S 118
Nexgenix Pharmaceuticals, LLC 119
Archer Biosciences, Inc 120
Lipocine Inc. 121
R&D Systems, Inc. 122
TAU Therapeutics, LLC 123
Tocagen Inc 124
CytomX, LLC. 125
Astrocytoma – Therapeutics Assessment 126
Assessment by Monotherapy Products 126
Assessment by Combination Products 127
Assessment by Route of Administration 128
Assessment by Molecule Type 130
Drug Profiles 132
Enzastaurin - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
Recentin - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
rindopepimut - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Avastin - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
Cilengitide - Drug Profile 139
Product Description 139
Mechanism of Action 139
R&D Progress 139
DCVax-L - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
IL13-PE38QQR - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
Recentin + Lomustine - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
Bevacizumab + Temozolomide - Drug Profile 146
Product Description 146
Mechanism of Action 146
R&D Progress 146
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Methotrexate + Temozolomide + Thiotepa + Vincristine + Stem cell transplantation + Radiation Therapy - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 149
Temozolomide + Radiation Therapy - Drug Profile 151
Product Description 151
Mechanism of Action 151
R&D Progress 151
Cilengitide + Temozolomide - Drug Profile 153
Product Description 153
Mechanism of Action 153
R&D Progress 153
Temozolomide + Radiation Therapy - Drug Profile 155
Product Description 155
Mechanism of Action 155
R&D Progress 155
Carmustine + O6-Benzylguanine + Radiation Therapy - Drug Profile 157
Product Description 157
Mechanism of Action 157
R&D Progress 157
O6-benzylguanine + Carmustine + Radiation therapy - Drug Profile 159
Product Description 159
Mechanism of Action 159
R&D Progress 159
Avastin + Temozolomide - Drug Profile 161
Product Description 161
Mechanism of Action 161
R&D Progress 161
Temozolomide - Drug Profile 163
Product Description 163
Mechanism of Action 163
R&D Progress 163
Temozolomide + Radiation Therapy - Drug Profile 164
Product Description 164
Mechanism of Action 164
R&D Progress 164
Temozolomide + Lomustine - Drug Profile 165
Product Description 165
Mechanism of Action 165
R&D Progress 165
Radiation Therapy + Procarbazine + ACNU - Drug Profile 166
Product Description 166
Mechanism of Action 166
R&D Progress 166
Radiation Therapy + ACNU - Drug Profile 167
Product Description 167
Mechanism of Action 167
R&D Progress 167
Thioguanine + Procarbazine + Lomustine + Vincristine - Drug Profile 168
Product Description 168
Mechanism of Action 168
R&D Progress 168
Carboplatin + Temozolomide + Thiotepa + Vincristine + Stem Cell Transplantion + Radiation Therapy - Drug Profile 170
Product Description 170
Mechanism of Action 170
R&D Progress 171
Temozolomide - Drug Profile 172
Product Description 172
Mechanism of Action 172
R&D Progress 172
Procarbazine + Lomustine + Vincristine - Drug Profile 174
Product Description 174
Mechanism of Action 174
R&D Progress 174
Temozolomide - Drug Profile 175
Product Description 175
Mechanism of Action 175
R&D Progress 175
Cytoxan + Melphalan + Autologous Stem Cell Transplantation - Drug Profile 176
Product Description 176
Mechanism of Action 176
R&D Progress 176
Carboplatinum + VP-16 + Thiotepa + Autologous Stem Cell Transplantation - Drug Profile 177
Product Description 177
Mechanism of Action 177
R&D Progress 177
Temodal + Radiation Therapy - Drug Profile 179
Product Description 179
Mechanism of Action 179
R&D Progress 179
Temozolomide - Drug Profile 180
Product Description 180
Mechanism of Action 180
R&D Progress 180
Temozolomide + Radiotherapy - Drug Profile 181
Product Description 181
Mechanism of Action 181
R&D Progress 181
Astrocytoma Therapeutics – Drug Profile Updates 182
Astrocytoma Therapeutics – Discontinued Products 188
Astrocytoma Therapeutics - Dormant Products 192
Astrocytoma – Product Development Milestones 207
Featured News & Press Releases 207
Aug 10, 2012: Genentech Announces Avastin Combination Therapy Meets Co-Primary Endpoint In Phase III Brain Cancer Study 207
Aug 08, 2012: Northwest Bio Expands Worldwide Production Capacity For DCVax-L 208
Aug 08, 2012: ImmunoCellular Announces Publication Of Phase I Trial Data Of ICT-107 In Prestigious Medical Journal, Cancer Immunology, Immunotherapy 208
Aug 08, 2012: Agenus Announces Publication Of Key Data Showing Antitumor Activity Of Prophage Vaccine In Clinical Cancer Research 209
Aug 01, 2012: Diffusion Pharma Successfully Completes First Cohort In Phase I/II Brain Cancer Trial Of Trans Sodium Crocetinate 210
Jul 26, 2012: Apogenix's APG101 Exceeds Expectations In Phase II Recurrent Glioblastoma Trial 210
Jul 26, 2012: Apogenix's APG101 Exceeds Expectations With Controlled Phase II Clinical Trial In Treatment Of Recurrent Glioblastoma 211
Jul 25, 2012: Fraunhofer IZI Receives Approval For Manufacturing Of Northwest Bio's DCVax-L Product 212
Jul 25, 2012: ImmunoCellular Therapeutics Announces Clearance Of IND Application For Phase I Study Of ICT-121 In Recurrent GBM 213
Jul 24, 2012: Researchers Study Vaccine Created From Patient Blood Cells For Treatement Of Brain Tumors 214
Appendix 215
Methodology 215
Coverage 215
Secondary Research 215
Primary Research 215
Expert Panel Validation 215
Contact Us 216
Disclaimer 216

List of Tables
Number of Products Under Development for Astrocytoma, H2 2012 14
Products under Development for Astrocytoma – Comparative Analysis, H2 2012 15
Number of Products under Development by Companies, H2 2012 17
Number of Products under Development by Companies, H2 2012 (Contd..1) 18
Number of Products under Development by Companies, H2 2012 (Contd..2) 19
Number of Products under Development by Companies, H2 2012 (Contd..3) 20
Number of Products under Development by Companies, H2 2012 (Contd..4) 21
Number of Products under Development by Companies, H2 2012 (Contd..5) 22
Number of Products under Investigation by Universities/Institutes, H2 2012 24
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 26
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 30
Comparative Analysis by Late Stage Development, H2 2012 31
Comparative Analysis by Mid Clinical Stage Development, H2 2012 32
Comparative Analysis by Early Clinical Stage Development, H2 2012 33
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 34
Products under Development by Companies, H2 2012 35
Products under Development by Companies, H2 2012 (Contd..1) 36
Products under Development by Companies, H2 2012 (Contd..2) 37
Products under Development by Companies, H2 2012 (Contd..3) 38
Products under Development by Companies, H2 2012 (Contd..4) 39
Products under Development by Companies, H2 2012 (Contd..5) 40
Products under Development by Companies, H2 2012 (Contd..6) 41
Products under Investigation by Universities/Institutes, H2 2012 42
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 43
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 45
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 46
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 47
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 48
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 57
F. Hoffmann-La Roche Ltd., H2 2012 58
Amgen Inc., H2 2012 59
Sanofi-Aventis, H2 2012 60
AstraZeneca PLC, H2 2012 61
Eli Lilly and Company, H2 2012 62
Genentech, Inc., H2 2012 63
MedImmune LLC, H2 2012 64
Merck & Co., Inc., H2 2012 65
Lentigen Corporation, H2 2012 66
Sangamo BioSciences, Inc., H2 2012 67
Plexxikon Inc., H2 2012 68
Celltrion, Inc., H2 2012 69
Ark Therapeutics Group plc, H2 2012 70
Novartis AG, H2 2012 71
Actelion Ltd, H2 2012 72
Eisai Co., Ltd., H2 2012 73
Nippon Shinyaku Co., Ltd., H2 2012 74
Pfizer Inc., H2 2012 75
Cell Therapeutics, Inc., H2 2012 76
Exelixis, Inc., H2 2012 77
Aduro BioTech, H2 2012 78
Merck KGaA, H2 2012 79
Novartis Pharmaceuticals Corporation, H2 2012 80
Celldex Therapeutics, Inc., H2 2012 81
ImmunoCellular Therapeutics, Ltd., H2 2012 82
Lixte Biotechnology Holdings, Inc., H2 2012 83
Northwest Biotherapeutics, Inc., H2 2012 84
Cleveland BioLabs, Inc., H2 2012 85
Oncothyreon Inc, H2 2012 86
Peregrine Pharmaceuticals, Inc., H2 2012 87
Pharmacyclics, Inc., H2 2012 88
PhytoMedical Technologies, Inc., H2 2012 89
Transgene SA, H2 2012 90
Prana Biotechnology Limited, H2 2012 91
Threshold Pharmaceuticals, Inc., H2 2012 92
Proximagen Neuroscience plc., H2 2012 93
Rexahn Pharmaceuticals, Inc., H2 2012 94
Spectrum Pharmaceuticals, Inc., H2 2012 95
INSYS Therapeutics, Inc., H2 2012 96
Ambit Biosciences Corporation, H2 2012 97
Immupharma Plc, H2 2012 98
Adnexus Therapeutics, Inc., H2 2012 99
immatics biotechnologies GmbH, H2 2012 100
Apogenix GmbH, H2 2012 101
Diffusion Pharmaceuticals LLC, H2 2012 102
MacroGenics, Inc., H2 2012 103
Fina Biotech, H2 2012 104
Nobelpharma Co., Ltd., H2 2012 105
Deciphera Pharmaceuticals, LLC, H2 2012 106
Vascular Biogenics Ltd., H2 2012 107
Stemline Therapeutics, Inc., H2 2012 108
BioCancell Therapeutics, Inc., H2 2012 109
Axelar AB, H2 2012 110
Advenchen Laboratories, LLC, H2 2012 111
Viral Genetics, Inc., H2 2012 112
Myriad Pharmaceuticals, Inc., H2 2012 113
NOXXON Pharma AG, H2 2012 114
ChemoCentryx, Inc., H2 2012 115
TVAX Biomedical, LLC, H2 2012 116
Sirnaomics, Inc., H2 2012 117
ZGene A/S, H2 2012 118
Nexgenix Pharmaceuticals, LLC, H2 2012 119
Archer Biosciences, Inc, H2 2012 120
Lipocine Inc., H2 2012 121
R&D Systems, Inc., H2 2012 122
TAU Therapeutics, LLC, H2 2012 123
Tocagen Inc, H2 2012 124
CytomX, LLC., H2 2012 125
Assessment by Monotherapy Products, H2 2012 126
Assessment by Combination Products, H2 2012 127
Assessment by Stage and Route of Administration, H2 2012 129
Assessment by Stage and Molecule Type, H2 2012 131
Astrocytoma Therapeutics – Drug Profile Updates 182
Astrocytoma Therapeutics – Discontinued Products 188
Astrocytoma Therapeutics – Discontinued Products (Contd..1) 189
Astrocytoma Therapeutics – Discontinued Products (Contd..2) 190
Astrocytoma Therapeutics – Discontinued Products (Contd..3) 191
Astrocytoma Therapeutics – Dormant Products 192
Astrocytoma Therapeutics – Dormant Products (Contd..1) 193
Astrocytoma Therapeutics – Dormant Products (Contd..2) 194
Astrocytoma Therapeutics – Dormant Products (Contd..3) 195
Astrocytoma Therapeutics – Dormant Products (Contd..4) 196
Astrocytoma Therapeutics – Dormant Products (Contd..5) 197
Astrocytoma Therapeutics – Dormant Products (Contd..6) 198
Astrocytoma Therapeutics – Dormant Products (Contd..7) 199
Astrocytoma Therapeutics – Dormant Products (Contd..8) 200
Astrocytoma Therapeutics – Dormant Products (Contd..9) 201
Astrocytoma Therapeutics – Dormant Products (Contd..10) 202
Astrocytoma Therapeutics – Dormant Products (Contd..11) 203
Astrocytoma Therapeutics – Dormant Products (Contd..12) 204
Astrocytoma Therapeutics – Dormant Products (Contd..13) 205
Astrocytoma Therapeutics – Dormant Products (Contd..14) 206

List of Figures
Number of Products under Development for Astrocytoma, H2 2012 14
Products under Development for Astrocytoma – Comparative Analysis, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 23
Late Stage Products, H2 2012 31
Mid Clinical Stage Products, H2 2012 32
Early Clinical Stage Products, H2 2012 33
Discovery and Pre-Clinical Stage Products, H2 2012 34
Assessment by Monotherapy Products, H2 2012 126
Assessment by Combination Products, H2 2012 127
Assessment by Route of Administration, H2 2012 128
Assessment by Stage and Route of Administration, H2 2012 129
Assessment by Molecule Type, H2 2012 130
Assessment by Stage and Molecule Type, H2 2012 131

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos